R
Robert Z. Orlowski
Researcher at University of Texas MD Anderson Cancer Center
Publications - 605
Citations - 40776
Robert Z. Orlowski is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 83, co-authored 543 publications receiving 34699 citations. Previous affiliations of Robert Z. Orlowski include University of Texas Health Science Center at Houston & Duke University.
Papers
More filters
Journal ArticleDOI
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Junling Zhuang,Junling Zhuang,Fazal Shirazi,Ram Kumar Singh,Isere Kuiatse,Hua Wang,Hans C. Lee,Zuzana Berkova,Allison Berger,Marc L. Hyer,Nibedita Chattopadhyay,Sakeena Syed,Judy Qiuju Shi,Jie Yu,Vaishali Shinde,Stephen Tirrell,Richard J. Jones,Zhiqiang Wang,R. Eric Davis,Robert Z. Orlowski +19 more
TL;DR: The data support the conclusion that UAE inhibition could be an attractive strategy to move forward to the clinic for patients with relapsed and/or refractory multiple myeloma.
Journal ArticleDOI
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma
Emily Rychak,Derek Mendy,Tao Shi,Yuhong Ning,Jim Leisten,Ling Lu,Karen Miller,Rama K. Narla,Robert Z. Orlowski,Heather Raymon,Chad C. Bjorklund,Anjan Thakurta,Anita Gandhi,Brian E. Cathers,Rajesh Chopra,Thomas O. Daniel,Antonia Lopez-Girona +16 more
TL;DR: Preclinical data is presented showing that the combination of pomalidomide with dexamethasone (PomDex) demonstrates potent anti‐proliferative and pro‐apoptotic activity in both lenalidmide‐sensitive and lenalidomides‐resistant MM cell lines.
Journal ArticleDOI
Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
TL;DR: Data indicate that SGI-1776 treatment in myeloma cell lines and CD138(+) myelomas cells elicits its deleterious effects through inhibition of translation and induction of autophagy.
Journal ArticleDOI
Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.
Suzanne E. Biehn,David Kirk,M. Patricia Rivera,Antonio Martinez,Amir H. Khandani,Robert Z. Orlowski +5 more
TL;DR: A case of an NHL patient who received rituximab and developed symptomatic, biopsy‐proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP) is described, suggesting that the incidence of BOOP following ritUXimab therapy may be higher than has been previously appreciated.
Journal ArticleDOI
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin
Suzanne E. Biehn,Dominic T. Moore,Peter M. Voorhees,Reynaldo Garcia,Mary Jo Lehman,E. Claire Dees,Robert Z. Orlowski +6 more
TL;DR: Findings support the possibility that the bortezomib/pegylated liposomal doxorubicin regimen may provide superior efficacy against relapsed/refractory multiple myeloma.